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Manuscript received September 10, 1996 ; revised December 17, 1996; accepted January 24, 1997. A major problem in cancer chemotherapy is the emergence of drug-resistant phenotypes during treatment. The most established mechanism contributing to drug resistance is the multidrug resistance mediated by P-glycoprotein (1-3). Pglycoprotein, encoded by the MDR1 gene, is a transmembrane protein that transports anticancer drugs out of cells. P-glycoprotein has an affinity for a broad spectrum of anticancer drugs, and overexpression of this transporter makes cells resistant to those drugs. One strategy for overcoming multidrug resistance is to modulate P-glycoprotein function by means of inhibitors (4) . To achieve this, a number of compounds that are capable of modulating P-glycoprotein activity have been identified (4 (4) (5) (6) (7) (8) (9) , which are all believed to be competitive and/or noncompetitive inhibitors of the P-glycoprotein-mediated transport of antitumor drugs.
Regression of Established
Although considerable effort has been devoted to finding successful combinations of these modulators and multidrugresistance-related anticancer drugs, the inherent and potential toxic effects of the modulators limit their chemotherapeutic advantages. When two modulators, such as CsA and verapamil, are combined in vitro, a lower concentration of each modulator is required to reverse multidrug resistance than the concentrations needed when the agents are used singly (10) . Modulator combinations might be useful, therefore, to avoid the doselimiting toxicity of the individual modulators. Another strategy that has been investigated is the specific targeting of P-glycoprotein-positive tumor tissue by use of anti-P-glycoprotein monoclonal antibodies (11, 12) . Antibodies administered alone or in combination with cytotoxic agents have been studied (13) (14) (15) (16) (17) (18) . We previously reported that two antibodies, MRK-16 and MRK-17, which recognize the external domain of human Pglycoprotein (19) , induced tumor regression in multidrug-resistant xenografts grown in athymic mice (13) . This tumor regression was induced by complement-dependent cytotoxicity and antibody-dependent, cell-mediated cytotoxicity. In addition, treatment with MRK-16 enhanced the antitumor activity of Adriamycin (ADM), without the potentiation of ADM toxicity, in an athymic mouse model of human colorectal carcinoma (14) .
MRK-16 has been shown to enhance synergistically the inhibitory activities of CsA and PSC 833 in vitro in ADMresistant sublines of leukemia and drugresistant carcinoma cell lines, but its effect on the activities of FK506 and verapamil was found to be additive (20) (21) (22) . Although the mechanism(s) of the synergistic interaction between MRK-16 and the cyclosporin derivatives has not been fully elucidated, the enhanced intracellular accumulation of CsA observed with MRK-16 treatment is likely to be relevant.
The findings described above led us to examine the antitumor activity of combination therapy with MRK-16, cyclosporin derivatives, and ADM in athymic mice bearing established human colorectal carcinomas.
Materials and Methods

Materials
CsA and PSC 833 were obtained from Sandoz Pharmaceuticals, Ltd. (Basel, Switzerland). ADM (as doxorubicin) and vincristine (VCR) were purchased from Kyowa Hakko Kogyo Co., Ltd. (Tokyo, Japan) and Shionogi Co., Ltd. (Osaka, Japan), respectively. Paclitaxel (Taxol) was purchased from Sigma Chemical Co. (St. Louis, MO). Galenical forms of etoposide (as Lastet) and mitoxantrone (as Novantron) were purchased from Nihon Kayaku, Co., Ltd. (Tokyo) and Lederle Japan, Ltd. (Tokyo), respectively. The murine monoclonal antibody MRK-16 was prepared as described previously (19) . Drink solutions of cyclosporin derivatives were also prepared as described previously (23, 24) . Solutions of ADM and MRK-16 were prepared in physiologic saline.
Animals and Tumors
Female 6-week-old BALB/c nu/nu mice weighing 19-23 g each were purchased from Clea Japan, Inc. (Tokyo, Japan). They were maintained under specific pathogen-free conditions at 25°C in an atmosphere with 50% humidity. Lighting was operated automatically on a 12-hour light/dark cycle. All animal studies were done under the guidelines of the Sandoz Tsukuba Research Institute, Sandoz Pharmaceuticals, Ltd., Tsukubashi, Ibaraki, Japan. Human colorectal carcinoma HCT-15 (CCL 225) cells were obtained from the American Type Culture Collection (Rockville, MD) through Dainippon Pharmaceutical Co. (Osaka, Japan). The ADM-resistant subline of HCT-15, HCT-15/ADM2-2, was established by continuous exposure of the parental cells to ADM at a concentration of 0.2 g/mL. HCT-15 cells were maintained in RPMI-1640 medium (Nissui, Tokyo, Japan) supplemented with 10% heatinactivated fetal bovine serum, 2 mM glutamine, and 100 g/mL kanamycin in an atmosphere containing 5% CO 2 at 37°C. HCT-15/ADM2-2 cells were maintained in the same growth medium supplemented additionally with 0.2 g/mL ADM. The human myelogenous leukemia cell line K562 was provided by Kohji Ezaki (Cancer Chemotherapy Center, Tokyo, Japan), and its subline resistant to ADM (K562/ADM) was established as described previously (25) .
Immunoblotting to Detect P-glycoprotein
P-glycoprotein in the plasma membrane fraction of cellular extracts was detected by means of immunoblotting, with the monoclonal antibody JSB-1 as the probe, according to a method described previously (26) .
In Vitro Growth Inhibition Assay
The growth inhibition assay used in this study has been described previously (27) . Here, the method was used with minor modifications. In brief, HCT-15 and HCT-15/ADM2-2 cells were seeded in 96-well tissue culture plates at a density of 5 × 10 3 cells/well. After incubating the cells for 24 hours, drug treatments were initiated. The cells were exposed to the drugs for 72 hours, and then relative cell growth was assessed by means of staining with 2,3-bis(2-methoxy-4-nitro-5-sulfophenyl)-5-[(phenylamino)carbonyl]-2H-tetrazolium hydroxide (Sigma Chemical Co.). After a 4-hour incubation with the tetrazolium dye, the absorbance at 450 nm was measured by use of a microplate reader (Molecular Devices Corp., Menlo Park, CA).
In Vivo Solid Tumor Studies
Antitumor activity in a xenograft model was evaluated as described previously (24) . A suspension of cells (10 7 cells in 0.1 mL Hanks' balanced salt solution) was injected into the right subaxillary region of individual athymic mice (day 0). The control and treatment groups contained 10 and five mice, respectively. Drug treatment was initiated after tumors were established (100-500 mm 3 , as estimated by caliper measurement), and it consisted of administration of a cyclosporin derivative, MRK-16, and ADM. The dose and route were as follows: 8 mg/kg body weight intravenously for ADM; 30 g/ mouse intravenously for MRK-16; 25 mg/kg body weight periorally for PSC 833; and 50 mg/kg body weight periorally for CsA. The cyclosporin derivatives and MRK-16 were given periorally 4 hours and intravenously 2 hours, respectively, before treatment with ADM. Some groups of mice with HCT-15/ ADM2-2 tumors were treated with multiple doses of MRK-16 (50 g/mouse intravenously on days 7, 10, 14, and 17). Tumor volume (V) was calculated by use of the following equation:
where a and b are the longest and shortest diameters of the tumor mass (in millimeters), respectively. Calculated tumor volumes were expressed in percentages as relative tumor volumes (RVs) by use of the following equation:
where V n is the tumor volume at day n and V 0 is the initial volume immediately before the first drug treatment. The criterion for antitumor activity was tumor growth inhibition. The T/C (treated/control) value was calculated as a percentage by use of the following formula:
T/C ‫ס‬ (mean RV of the treated animals)/(mean RV of the control animals) × 100.
Antibody Binding Assay
Cell surface binding of MRK-16 was determined as described previously (28) 
Statistical Analysis
Statistical analysis involving the comparison of entire inhibition curves from the in vitro growthinhibition studies and from the in vivo solid-tumor studies was performed by use of repeated measure analysis of variance (ANOVA) [Bonferroni/Dann (29)] with StatView software (version 4.02 for Macintosh, Abaeus Concepts, Inc., Berkeley, CA). Presented P values are two-sided. Synergy of MRK-16 and the cyclosporin derivatives was analyzed by means of the fractional product method (30, 31) . For the in vitro growth inhibition study, if the observed inhibition is less than the calculated inhibition, a synergistic effect is suggested; if the observed inhibition is similar to the calculated inhibition, an additive effect is suggested. For the solid tumor study, if the observed T/C value is less than the calculated T/C value, synergy is suggested; if the observed and calculated T/C values are the same, an additive effect is suggested. In the solid-tumor study, significant differences between treated groups of mice were determined by use of the Mann-Whitney U test. In analyzing results from the antibody-binding assay, P values were determined by means of the Student's t test for the comparison of fluorescence values obtained with and without cyclosporin derivatives.
Results
P-glycoprotein Expression and Drug Sensitivity Exhibited by HCT-15 and HCT-15/ADM2-2 Cells
Immunoblot analysis, using the anti-Pglycoprotein monoclonal antibody JSB-1 as the probe, demonstrated that the human colorectal tumor cell line HCT-15 intrinsically expressed P-glycoprotein (Fig. 1,  A) . Densitometry revealed that the ADMresistant subline HCT-15/ADM2-2 expressed five times more P-glycoprotein than HCT-15. In an in vitro growth inhibition assay, the drug concentrations that produced 50% growth inhibition of HCT-15 and HCT-15/ADM2-2 cells, respectively, were 252 and 1960 ng/mL for ADM, 192 and 1040 ng/mL for VCR, 326 and 1570 ng/mL for paclitaxel, 1740 and 5480 ng/mL for etoposide, and 87 and 272 ng/mL for mitoxantrone. Thus, the HCT-15/ADM2-2 cell line was eight times more resistant to ADM than the HCT-15 cell line in vitro, and the resistant cells showed cross-resistance to VCR, paclitaxel, etoposide, and mitoxantrone.
Effect of MRK-16 on Sensitization by Cyclosporin Derivatives to ADM and VCR In Vitro
We investigated the effect of the MRK-16 monoclonal antibody on the antiproliferative activities of combinations of ADM or VCR and cyclosporin derivatives against HCT-15 cells and HCT-15/ ADM2-2 cells in vitro (Fig. 1, B) . Tumor cell growth rates were determined after a 72-hour incubation with the drugs by means of an assay that employed staining with 2,3-bis(2-methoxy-4-nitro-5-sulfophenyl)-5-[(phenylamino)carbonyl]-2H-tetrazolium hydroxide. When ADM or VCR was combined with either PSC 833 at 0.05 g/mL or CsA at 0.3 g/mL, cell growth was inhibited by up to 50%. Although MRK-16, by itself and with the anticancer agents, minimally reduced the growth rate, MRK-16 in combination with a cyclosporin derivative significantly enhanced the growth-inhibitory activities of ADM and VCR. The combined effects were synergistic, as determined by an analysis that utilized the fractional product method.
Antitumor Activity in a Xenograft Model of Combination Treatment with ADM, Cyclosporin Derivatives, and MRK-16
The effects of the ternary combination therapy were explored in vivo by use of established xenografts in athymic mice ( Fig. 2; Table 1 ). A pilot study indicated that treatment with either PSC 833 at 25 mg/kg body weight or CsA at 50 mg/kg body weight reduced the maximum tolerated single intravenous dose of ADM from 12 to 8 mg/kg body weight. Therefore, in a series of treatments, we fixed the dose of ADM at 8 mg/kg.
The HCT-15 xenografts achieved a volume of more than 100 mm 3 on day 11. At that time, the mice were treated with ADM (intravenously) and/or MRK-16 (30 g/mouse, intravenously) or with ADM and a cyclosporin derivative (PSC 833 at 25 mg/kg body weight, periorally, or CsA at 50 mg/kg body weight, periorally) with or without MRK-16 (Fig. 2,  upper panels) . Single agent treatment with ADM slightly inhibited the growth of the HCT-15 xenografts by approximately 20%, as measured 14 days after the treatment (Table 1) . While either MRK-16 or the cyclosporin derivatives slightly enhanced the antitumor activity of ADM, the triple combinations containing a cyclosporin derivative, MRK-16, and ADM resulted in more pronounced growth inhibition of the xenografts (T/C <40%).
Additional experiments were designed to examine the effects of the ternary treatments on tumors formed by HCT-15/ ADM2-2 cells, which express higher amounts of P-glycoprotein than HCT-15 cells (Fig. 2, lower panels) . The average volume of HCT-15/ADM2-2 tumors became greater than 100 mm 3 on day 7 after tumor cell injection. At this time, ADM and the cyclosporin derivatives were given. Two different amounts of MRK-16 were used in these experiments. Some mice received a single dose of 30 g/ mouse intravenously on day 7 (30 g × 1); others received 50 g MRK-16 per day intravenously on days 7, 10, 14, and 17 (50 g × 4). The ternary combinations significantly inhibited tumor growth, while MRK-16 combined with ADM in the absence of the cyclosporin derivatives resulted in moderate inhibition. Interestingly, the HCT-15/ADM2-2 xenografts were more sensitive to MRK-16 treatment than the HCT-15 xenografts ( Table 1) 
Effect of CsA and PSC 833 on Binding of MRK-16 to the Cell Surface
To examine a possibility that CsA and PSC 833 affect the association of MRK-16 with P-glycoprotein, we measured the binding of MRK-16 to HCT-15 cells and HCT-15/ADM2-2 cells in the presence of cyclosporin derivatives (Fig. 3) . Both PSC 833 and CsA at 6 g/mL increased the binding of MRK-16 to P-glycoprotein on the cell surface. The activity of the cyclosporin derivatives in enhancing MRK-16 binding to P-glycoprotein was more prominent with HCT-15/ADM2-2 cells than with parental HCT-15 cells.
Discussion
A number of studies (1-3) have demonstrated thus far that P-glycoprotein expression is an important indicator of therapeutic outcome. Therefore, efforts to overcome P-glycoprotein-mediated drug resistance have been directed at inhibiting P-glycoprotein function. These efforts have included the use of chemosensitizing agent combinations and inhibitory antibodies that recognize the external domain of P-glycoprotein. In this study, we used PSC 833, CsA, and MRK-16 as modulators of P-glycoprotein function. PSC 833 in combination with multidrug-resistancerelated anticancer drugs has resulted in the elimination of murine tumors in mice (24) . In addition, treatment with PSC 833 and ADM has resulted in the inhibition of growth of established HCT-15 xenografts; however, this treatment was not curative. MRK-16 in combination with ADM was also unable to induce complete HCT-15 tumor regression (14) . These findings suggest that both PSC 833 and MRK-16 are potent agents, but they are still insufficient to induce the complete regression of established tumors. In this study, we combined MRK-16 with the cyclosporin derivatives PSC 833 and CsA in an attempt to establish a more effective Cell growth was measured by means of a tetrazolium dye assay, as described in the "Materials and Methods" section. Growth rates are expressed as percentages of the control rate (i.e., the growth rate without drugs and MRK-16) and are plotted in relation to the MRK-16 concentration. The individual culture conditions were as follows: no drug (᭹); the anticancer drug method for circumventing P-glycoprotein-mediated drug resistance.
Our results indicate that combination therapy with MRK-16 and cyclosporin derivatives is quite effective in blocking multidrug resistance in a xenograft model. In addition, it is noteworthy that the complete regression of some established tumors was evident in mice receiving MRK-16, a cyclosporin derivative, and ADM (Fig. 2) . Interestingly, a single treatment with MRK-16 in combination with ADM and cyclosporin treatment induced the disappearance of some HCT-15/ADM2-2 xenografts but not of HCT-15 xenografts (Fig. 2) . The densitometric analysis of immunoblots revealed a Pglycoprotein expression level in HCT-15/ ADM2-2 cells that was approximately five times higher than that in HCT-15 cells. These findings suggest that the combination treatment is more effective against tumors with higher expression of P-glycoprotein. In addition, the activity of MRK-16 can be associated with its specific binding to P-glycoprotein, since an irrelevant antibody that does not bind to the surface of the tumor cells did not affect treatment outcome, as previously reported (14) . It is possible that an antibody directed against a different cell surface antigen might be able to induce antigendependent immune responses similar to those observed with MRK-16 and MRK-17 (13) ; however, it is likely that the antitumor activity of anti-P-glycoprotein antibodies in combination therapies involves more than just these responses.
The drug-resistance reversal activities of CsA and PSC 833 in vitro were synergistically enhanced by MRK-16 treatment (20) (21) (22) . The synergistic interaction between MRK-16 and CsA can be attributed to the enhanced intracellular accumulation of CsA in the presence of the anti- body (20) . However, a previous study (22) has demonstrated that the intracellular accumulation of PSC 833 is not increased by treatment with MRK-16. Furthermore, it has been shown that PSC 833, unlike CsA, is not transported by Pglycoprotein (32) . Therefore, even if MRK-16 inhibits P-glycoprotein function, the accumulation of PSC 833 in Pglycoprotein-positive cells might change minimally.
The question arises as to how MRK-16 synergistically enhances the reversal activity of PSC 833. We hypothesize that PSC 833 modulates molecular interactions between the antibody and P-glycoprotein. We have demonstrated that PSC 833 increases MRK-16 binding to Pglycoprotein (Fig. 3) . This effect could contribute to the synergistic enhancement of the multidrug-resistance-reversal activity caused by the MRK-16 plus PSC 833 combination. We have detected a similar effect on MRK-16 binding mediated by CsA.
In conclusion, MRK-16 enhances the antitumor activity of combination treatment with cyclosporin and ADM in an established P-glycoprotein-positive xenograft model. The ternary treatment combination is more effective against tumors with higher expression of P-glycoprotein. In clinical trials of MRK-16 for the circumvention of drug-resistance, combining the antibody with cyclosporin derivatives and anticancer drugs could present distinct advantages in the reversal of that resistance. ‡Ratio (as a percentage) of the tumor volume of treated groups (T) relative to that of control groups (C). §MRK-16 was given intravenously either once per mouse (30 g × 1) on day 11 (HCT-15 xenografts) or day 7 (HCT-15/ADM2-2 xenografts) or four times per mouse (50 g × 4) on days 7, 10, 12, and 14.
ADM and the cyclosporin derivatives were given intravenously and periorally, respectively, on day 11 (HCT-15 xenografts) or day 7 (HCT-15/ADM2-2 xenografts). The cyclosporin derivatives were given 4 hours before the ADM treatment.
¶Synergistic as determined by the fractional product method. #The ratio of tumor-free mice to total number of mice. Tumor-free mice on day 63 were considered cured. Note: Superscript numbers 1-6 indicate significant difference from the control group 1, 2 , from the ADMonly group 3, 4 , and from the MRK-16 nontreated group 5, 6 by Mann-Whitney U test ( 1,3,5 : P<.01; 2, 4, 6 : P<.05). 
